How to Help Your Patients Find Lynparza In Stock: A Provider's Guide

Prescribing Lynparza (olaparib) is just the beginning. For oncology providers, the real challenge is getting this specialty medication into patients' hands quickly—especially given the time-sensitive nature of maintenance therapy after platinum-based chemotherapy. This guide covers practical, step-by-step strategies for helping your patients access Lynparza without unnecessary delays in 2026.

Why Timing Matters for Lynparza Patients

For ovarian cancer patients on Lynparza maintenance therapy, the post-chemotherapy window is critical. Clinical guidelines recommend initiating Lynparza within approximately 8 weeks of the last platinum-based chemotherapy dose for maintenance indications. Administrative delays that push past this window may have clinical implications. Starting the access process early—before chemotherapy even concludes—is essential.

Step 1: Order Biomarker Testing Early

Every Lynparza indication requires biomarker testing. Don't wait until chemotherapy is complete to order this testing. Germline and somatic BRCA testing typically takes 1–4 weeks, and insurers require documented results as part of the prior authorization process.

Order germline BRCA testing (blood/saliva) for all patients who may be candidates for Lynparza indications that require gBRCAm

Order tumor somatic testing (HRD panel) if the patient may qualify for the bevacizumab combination or HRR-mutated prostate cancer indication

Confirm the testing platform used is FDA-approved as a companion diagnostic for Lynparza

Step 2: Initiate Prior Authorization Proactively

Don't wait until the prescription is written to start the PA process. Many practices successfully submit PA requests while the patient is still on chemotherapy, using projected treatment response and expected genetic testing results. This allows PA to be in place—or at least far along—when Lynparza is ready to start.

Key documentation to include in PA submissions:

Pathology report confirming cancer diagnosis and histology

Biomarker test results (germline BRCA and/or tumor somatic report)

Treatment history including chemotherapy regimen, cycle dates, and response assessment

ECOG performance status (required by some payers)

Letter of medical necessity emphasizing the time-sensitive nature of initiating maintenance therapy

Step 3: Leverage AstraZeneca's Access 360 Program

Access 360 (1-844-275-2360 or myaccess360.com) is AstraZeneca's patient support hub for Lynparza. For providers, it functions as an extension of your access team—handling PA logistics, specialty pharmacy routing, and patient financial assistance enrollment.

Enrolling your patient in Access 360 at the time of prescribing (or earlier) is one of the highest-impact steps you can take to reduce time to first fill. Access 360 case managers are familiar with individual payer requirements and can often flag issues before they become denials.

Step 4: Route to the Right Specialty Pharmacy

Lynparza cannot be filled at standard retail pharmacies. The prescription must go to a specialty pharmacy—and specifically, one that is in the patient's insurance network. Routing to an out-of-network specialty pharmacy can result in coverage denial or dramatically higher out-of-pocket costs.

Best practice: confirm the patient's insurance plan and identify the preferred specialty pharmacy before sending the prescription. Your practice's oncology pharmacist, Access 360, or the patient's insurance member services line can provide this information.

Step 5: Help Patients Understand Financial Assistance

Cost shock is a real reason patients delay or skip picking up Lynparza. Proactively connecting patients with financial assistance programs before they go to the pharmacy can prevent this:

Commercially insured: Enroll in Lynparza Co-pay Savings Program through Access 360. Eligible patients may pay as little as $0/month.

Uninsured/underinsured: AZ&Me Prescription Savings Program provides free drug for qualifying patients. Enrollment is annual; 90-day supplies shipped every quarter.

Medicare patients: Not eligible for manufacturer copay programs, but may qualify for assistance from independent foundations (Patient Advocate Foundation, CancerCare, HealthWell Foundation). Explore the Part D Medicare Prescription Payment Plan to spread costs across the year.

Handling PA Denials Effectively

First-submission denials are common for specialty oncology drugs. When Lynparza PA is denied:

Review the denial reason carefully—common reasons include missing documentation, insufficient biomarker test details, or step therapy requirements

Submit an appeal with additional clinical detail and, if applicable, supporting literature

Request a peer-to-peer review with the payer's medical director—oncologist-to-physician conversations often reverse denials

During the appeal process, request bridge supply through Access 360 to avoid treatment gaps

How medfinder Supports Your Patients

For patients who need help identifying a specific specialty pharmacy in their area that carries Lynparza, medfinder for providers does pharmacy canvassing on behalf of your patients. This is particularly helpful for patients in rural or suburban areas without easy access to major specialty pharmacy locations.

For detailed information on patient savings programs, see our guide: How to Save Money on Lynparza in 2026.